Tokyo Tape
Sign in
← GNI Group

Quarterly report · Q2

2160.TEDINET S100P1F0
Period2022-01-01 → 2022-06-30
Filed2022-08-15
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 62
MetricValuePeriodScopeSource row
Revenue¥8.2bn2022-01-01 → 2022-06-30Cons.Revenue IFRS
Revenue¥4.2bn2022-04-01 → 2022-06-30dCons.Revenue IFRS
Revenue¥12.7bn2021-01-01 → 2021-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥6.5bn2021-01-01 → 2021-06-30Cons.Revenue IFRS
Revenue¥2.6bn2021-04-01 → 2021-06-30dCons.Revenue IFRS
Operating income¥1.0bn2022-01-01 → 2022-06-30Cons.Operating profit loss IFRS
Operating income¥526m2022-04-01 → 2022-06-30dCons.Operating profit loss IFRS
Operating income¥1.5bn2021-01-01 → 2021-06-30Cons.Operating profit loss IFRS
Operating income¥682m2021-04-01 → 2021-06-30dCons.Operating profit loss IFRS
Profit before tax¥790m2022-01-01 → 2022-06-30Cons.Profit loss before tax IFRS
Profit before tax¥443m2022-04-01 → 2022-06-30dCons.Profit loss before tax IFRS
Profit before tax¥1.1bn2021-01-01 → 2021-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥1.2bn2021-01-01 → 2021-06-30Cons.Profit loss before tax IFRS
Profit before tax¥522m2021-04-01 → 2021-06-30dCons.Profit loss before tax IFRS
Net income (owners)¥676m2022-01-01 → 2022-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥325m2022-04-01 → 2022-06-30dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥1.1bn2021-01-01 → 2021-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥941m2021-01-01 → 2021-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥509m2021-04-01 → 2021-06-30dCons.Profit loss attributable to owners of parent IFRS
Net income¥198m2022-01-01 → 2022-06-30Cons.Profit loss IFRS
Net income¥126m2022-04-01 → 2022-06-30dCons.Profit loss IFRS
Net income¥55m2021-01-01 → 2021-12-31Cons.Profit loss IFRS (5-year summary)
Net income¥745m2021-01-01 → 2021-06-30Cons.Profit loss IFRS
Net income¥309m2021-04-01 → 2021-06-30dCons.Profit loss IFRS
Total assets¥35.3bnat 2022-06-30Cons.Assets IFRS
Total assets¥30.3bnat 2021-12-31Cons.Assets IFRS
Total assets¥29.0bnat 2021-06-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥13.5bnat 2022-06-30Cons.Liabilities IFRS
Total liabilities¥11.0bnat 2021-12-31Cons.Liabilities IFRS
Net assets / equity¥21.8bnat 2022-06-30Cons.Equity IFRS
Net assets / equity¥19.3bnat 2021-12-31Cons.Equity IFRS
Net assets / equity¥19.1bnat 2021-06-30Cons.Equity IFRS
Net assets / equity¥12.8bnat 2020-12-31dCons.Equity IFRS
Equity (owners)¥22.0bnat 2022-06-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥18.9bnat 2021-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥17.9bnat 2021-06-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥14.5bnat 2022-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥14.4bnat 2021-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥13.8bnat 2021-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥10.3bnat 2020-12-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥389m2022-01-01 → 2022-06-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥552m2021-01-01 → 2021-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥1.1bn2021-01-01 → 2021-06-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥1.5bn2022-01-01 → 2022-06-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥261m2021-01-01 → 2021-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥1.0bn2021-01-01 → 2021-06-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥267m2022-01-01 → 2022-06-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow¥2.9bn2021-01-01 → 2021-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow¥2.9bn2021-01-01 → 2021-06-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥14.252022-01-01 → 2022-06-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥6.862022-04-01 → 2022-06-30dCons.Basic earnings loss per share IFRS
EPS (basic)¥22.722021-01-01 → 2021-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥20.32021-01-01 → 2021-06-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥10.782021-04-01 → 2021-06-30dCons.Basic earnings loss per share IFRS
EPS (diluted)¥14.182022-01-01 → 2022-06-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥6.832022-04-01 → 2022-06-30dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥22.082021-01-01 → 2021-12-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥19.732021-01-01 → 2021-06-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥10.592021-04-01 → 2021-06-30dCons.Diluted earnings loss per share IFRS
Equity ratio62.5%at 2022-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio62.3%at 2021-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio61.9%at 2021-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 18
SegmentItemPeriodValue
jpcrp040300-q2r_E05712-000Medical Devicereportable segmentrevenue2022-01-01 → 2022-06-30¥1.2bn
jpcrp040300-q2r_E05712-000Medical Devicereportable segmentrevenue external2022-01-01 → 2022-06-30¥1.2bn
jpcrp040300-q2r_E05712-000Medical Devicereportable segmentsegment profit2022-01-01 → 2022-06-30¥526m
jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segmentrevenue2022-01-01 → 2022-06-30¥7.0bn
jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segmentrevenue external2022-01-01 → 2022-06-30¥7.0bn
jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segmentsegment profit2022-01-01 → 2022-06-30¥479m
—segment totalrevenue2022-01-01 → 2022-06-30¥8.2bn
—segment totalrevenue external2022-01-01 → 2022-06-30¥8.2bn
—segment totalsegment profit2022-01-01 → 2022-06-30¥1.0bn
jpcrp040300-q2r_E05712-000Medical Devicereportable segmentrevenue2021-01-01 → 2021-06-30¥1.0bn
jpcrp040300-q2r_E05712-000Medical Devicereportable segmentrevenue external2021-01-01 → 2021-06-30¥1.0bn
jpcrp040300-q2r_E05712-000Medical Devicereportable segmentsegment profit2021-01-01 → 2021-06-30¥390m
jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segmentrevenue2021-01-01 → 2021-06-30¥5.5bn
jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segmentrevenue external2021-01-01 → 2021-06-30¥5.5bn
jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segmentsegment profit2021-01-01 → 2021-06-30¥1.1bn
—segment totalrevenue2021-01-01 → 2021-06-30¥6.5bn
—segment totalrevenue external2021-01-01 → 2021-06-30¥6.5bn
—segment totalsegment profit2021-01-01 → 2021-06-30¥1.5bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 734
ItemContextValueUnit
Liabilities IFRSPrior1YearInstant11030734000JPY
Liabilities IFRSCurrentQuarterInstant13504294000JPY
Share capital IFRSPrior1YearInstant10884332000JPY
Share capital IFRSCurrentQuarterInstant10884332000JPY
Capital surplus IFRSPrior1YearInstant6224649000JPY
Capital surplus IFRSCurrentQuarterInstant6224649000JPY
Treasury shares IFRSPrior1YearInstant-645000JPY
Treasury shares IFRSCurrentQuarterInstant-645000JPY
Retained earnings IFRSPrior1YearInstant307535000JPY
Retained earnings IFRSCurrentQuarterInstant983981000JPY
Other components of equity IFRSPrior1YearInstant1444437000JPY
Other components of equity IFRSCurrentQuarterInstant3948241000JPY
Equity attributable to owners of parent IFRSPrior1YearInstant18860309000JPY
Equity attributable to owners of parent IFRSCurrentQuarterInstant22040559000JPY
Non controlling interests IFRSPrior1YearInstant405936000JPY
Non controlling interests IFRSCurrentQuarterInstant-278058000JPY
Equity IFRSPrior1YearInstant19266246000JPY
Equity IFRSCurrentQuarterInstant21762501000JPY
Liabilities and equity IFRSPrior1YearInstant30296980000JPY
Liabilities and equity IFRSCurrentQuarterInstant35266795000JPY
Revenue IFRSPrior1YTDDuration6465175000JPY
Revenue IFRSCurrentYTDDuration8154817000JPY
Cost of sales IFRSPrior1YTDDuration785692000JPY
Cost of sales IFRSCurrentYTDDuration1134655000JPY
Gross profit IFRSPrior1YTDDuration5679483000JPY
Gross profit IFRSCurrentYTDDuration7020162000JPY
Selling general and administrative expenses IFRSPrior1YTDDuration3677925000JPY
Selling general and administrative expenses IFRSCurrentYTDDuration4765750000JPY
Research and development expenditure recognized as expense during period IFRSPrior1YTDDuration864935000JPY
Research and development expenditure recognized as expense during period IFRSCurrentYTDDuration1089540000JPY
Other income IFRSPrior1YTDDuration419896000JPY
Other income IFRSCurrentYTDDuration54380000JPY
Other expenses IFRSPrior1YTDDuration100889000JPY
Other expenses IFRSCurrentYTDDuration214584000JPY
Operating profit loss IFRSPrior1YTDDuration1455628000JPY
Operating profit loss IFRSCurrentYTDDuration1004668000JPY
Finance income IFRSPrior1YTDDuration32809000JPY
Finance income IFRSCurrentYTDDuration175775000JPY
Finance costs IFRSPrior1YTDDuration290762000JPY
Finance costs IFRSCurrentYTDDuration390055000JPY
Profit loss before tax IFRSPrior1YTDDuration1197676000JPY
Profit loss before tax IFRSCurrentYTDDuration790388000JPY
Income tax expense IFRSPrior1YTDDuration452898000JPY
Income tax expense IFRSCurrentYTDDuration592469000JPY
Profit loss IFRSPrior1YTDDuration744778000JPY
Profit loss IFRSCurrentYTDDuration197918000JPY
Profit loss attributable to owners of parent IFRSPrior1YTDDuration941326000JPY
Profit loss attributable to owners of parent IFRSCurrentYTDDuration676446000JPY
Profit loss attributable to non controlling interests IFRSPrior1YTDDuration-196548000JPY
Profit loss attributable to non controlling interests IFRSCurrentYTDDuration-478528000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2021-12-31pass
balance sheet identityconsolidated 2022-06-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2021-01-01/2021-06-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-01-01/2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · operating cash flowconsolidated 2021-01-01/2021-06-30pass
statement vs summary · operating cash flowconsolidated 2022-01-01/2022-06-30pass
statement vs summary · revenueconsolidated 2021-01-01/2021-06-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-06-30pass
statement vs summary · revenueconsolidated 2022-01-01/2022-06-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-06-30pass
statement vs summary · total assetsconsolidated 2021-12-31pass
statement vs summary · total assetsconsolidated 2022-06-30pass